Immunotherapy of peritoneal carcinomatosis with the antibody catumaxomab in colon, gastric, or pancreatic cancer: an open-label, multicenter, phase I/II trial
Background: Peritoneal carcinomatosis (PC) is common in gastrointestinal (GI) cancer and there is no effective standard treatment. We investigated the tolerability and maximum tolerated dose (MTD) of the trifunctional antibody catumaxomab in patients with PC. Methods: In this openlabel, phase I/II c...
Saved in:
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
February 18, 2011
|
| In: |
Onkologie
Year: 2011, Volume: 34, Issue: 3, Pages: 101-108 |
| ISSN: | 1423-0240 |
| DOI: | 10.1159/000324667 |
| Online Access: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1159/000324667 Verlag, lizenzpflichtig, Volltext: https://www.karger.com/Article/FullText/324667 
|
| Author Notes: | Michael A. Ströhlein, Florian Lordick, Dominik Rüttinger, Klaus-Uwe Grützner, Oliver C. Schemanski, Michael Jäger, Horst Lindhofer, Michael Hennig, Karl-Walter Jauch, Christian Peschel, Markus M. Heiss |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 181988452X | ||
| 003 | DE-627 | ||
| 005 | 20230710105204.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 221025s2011 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1159/000324667 |2 doi | |
| 035 | |a (DE-627)181988452X | ||
| 035 | |a (DE-599)KXP181988452X | ||
| 035 | |a (OCoLC)1389762322 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Ströhlein, Michael |d 1971- |e VerfasserIn |0 (DE-588)124591221 |0 (DE-627)363430075 |0 (DE-576)294247343 |4 aut | |
| 245 | 1 | 0 | |a Immunotherapy of peritoneal carcinomatosis with the antibody catumaxomab in colon, gastric, or pancreatic cancer |b an open-label, multicenter, phase I/II trial |c Michael A. Ströhlein, Florian Lordick, Dominik Rüttinger, Klaus-Uwe Grützner, Oliver C. Schemanski, Michael Jäger, Horst Lindhofer, Michael Hennig, Karl-Walter Jauch, Christian Peschel, Markus M. Heiss |
| 264 | 1 | |c February 18, 2011 | |
| 300 | |a 8 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 25.10.2022 | ||
| 520 | |a Background: Peritoneal carcinomatosis (PC) is common in gastrointestinal (GI) cancer and there is no effective standard treatment. We investigated the tolerability and maximum tolerated dose (MTD) of the trifunctional antibody catumaxomab in patients with PC. Methods: In this openlabel, phase I/II clinical trial, patients with epithelial cell adhesion molecule (EpCAM)-positive PC from GI cancer received 4 sequential intraperitoneal catumaxomab infusions: day 0: 10 µg; day 3: 10 or 20 µg; day 7: 30, 50, or 100 µg; and day 10: 50, 100, or 200 µg. Dose escalation was guided by dose-limiting toxicities. Results: The MTD was 10, 20, 50, and 200 µg on days 0, 3, 7, and 10, respectively. Catumaxomab had an acceptable safety profile: Most common treatment-related adverse events (at the MTD) were fever, vomiting, and abdominal pain. At final examination, 11/17 evaluable patients (65%) were progression free: 1 patient had a complete and 3 a partial response. Median overall survival from the time of diagnosis of PC was 502 days. Conclusions: Intraperitoneal catumaxomab is a promising option for the treatment of PC from GI cancer. | ||
| 700 | 1 | |a Lordick, Florian |d 1966- |e VerfasserIn |0 (DE-588)114389349 |0 (DE-627)52295085X |0 (DE-576)289795567 |4 aut | |
| 700 | 1 | |a Rüttinger, Dominik |e VerfasserIn |4 aut | |
| 700 | 1 | |a Grützner, Klaus-Uwe |e VerfasserIn |4 aut | |
| 700 | 1 | |a Schemanski, Oliver C. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Jäger, Michael |e VerfasserIn |4 aut | |
| 700 | 1 | |a Lindhofer, Horst |e VerfasserIn |4 aut | |
| 700 | 1 | |a Hennig, Michael |e VerfasserIn |4 aut | |
| 700 | 1 | |a Jauch, Karl-Walter |e VerfasserIn |4 aut | |
| 700 | 1 | |a Peschel, Christian |e VerfasserIn |4 aut | |
| 700 | 1 | |a Heiss, Markus M. |e VerfasserIn |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Onkologie |d Basel : Karger, 1978 |g 34(2011), 3, Seite 101-108 |h Online-Ressource |w (DE-627)300595417 |w (DE-600)1483097-8 |w (DE-576)105282863 |x 1423-0240 |7 nnas |a Immunotherapy of peritoneal carcinomatosis with the antibody catumaxomab in colon, gastric, or pancreatic cancer an open-label, multicenter, phase I/II trial |
| 773 | 1 | 8 | |g volume:34 |g year:2011 |g number:3 |g pages:101-108 |g extent:8 |a Immunotherapy of peritoneal carcinomatosis with the antibody catumaxomab in colon, gastric, or pancreatic cancer an open-label, multicenter, phase I/II trial |
| 856 | 4 | 0 | |u https://doi.org/10.1159/000324667 |x Verlag |x Resolving-System |z lizenzpflichtig |3 Volltext |
| 856 | 4 | 0 | |u https://www.karger.com/Article/FullText/324667 |x Verlag |z lizenzpflichtig |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20221025 | ||
| 993 | |a Article | ||
| 994 | |a 2011 | ||
| 998 | |g 114389349 |a Lordick, Florian |m 114389349:Lordick, Florian |d 50000 |e 50000PL114389349 |k 0/50000/ |p 2 | ||
| 999 | |a KXP-PPN181988452X |e 4201669440 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"name":{"displayForm":["Michael A. Ströhlein, Florian Lordick, Dominik Rüttinger, Klaus-Uwe Grützner, Oliver C. Schemanski, Michael Jäger, Horst Lindhofer, Michael Hennig, Karl-Walter Jauch, Christian Peschel, Markus M. Heiss"]},"recId":"181988452X","note":["Gesehen am 25.10.2022"],"origin":[{"dateIssuedKey":"2011","dateIssuedDisp":"February 18, 2011"}],"id":{"eki":["181988452X"],"doi":["10.1159/000324667"]},"language":["eng"],"type":{"media":"Online-Ressource","bibl":"article-journal"},"person":[{"role":"aut","given":"Michael","display":"Ströhlein, Michael","family":"Ströhlein"},{"role":"aut","given":"Florian","family":"Lordick","display":"Lordick, Florian"},{"display":"Rüttinger, Dominik","family":"Rüttinger","given":"Dominik","role":"aut"},{"role":"aut","display":"Grützner, Klaus-Uwe","family":"Grützner","given":"Klaus-Uwe"},{"role":"aut","family":"Schemanski","display":"Schemanski, Oliver C.","given":"Oliver C."},{"family":"Jäger","display":"Jäger, Michael","given":"Michael","role":"aut"},{"family":"Lindhofer","display":"Lindhofer, Horst","given":"Horst","role":"aut"},{"given":"Michael","family":"Hennig","display":"Hennig, Michael","role":"aut"},{"family":"Jauch","display":"Jauch, Karl-Walter","given":"Karl-Walter","role":"aut"},{"role":"aut","given":"Christian","family":"Peschel","display":"Peschel, Christian"},{"given":"Markus M.","display":"Heiss, Markus M.","family":"Heiss","role":"aut"}],"physDesc":[{"extent":"8 S."}],"title":[{"subtitle":"an open-label, multicenter, phase I/II trial","title":"Immunotherapy of peritoneal carcinomatosis with the antibody catumaxomab in colon, gastric, or pancreatic cancer","title_sort":"Immunotherapy of peritoneal carcinomatosis with the antibody catumaxomab in colon, gastric, or pancreatic cancer"}],"relHost":[{"type":{"bibl":"periodical","media":"Online-Ressource"},"id":{"zdb":["1483097-8"],"issn":["1423-0240"],"eki":["300595417"]},"language":["ger"],"origin":[{"publisherPlace":"Basel","dateIssuedDisp":"1978-2013","publisher":"Karger","dateIssuedKey":"1978"}],"physDesc":[{"extent":"Online-Ressource"}],"title":[{"title":"Onkologie","subtitle":"international journal for cancer research and treatment","title_sort":"Onkologie"}],"part":{"pages":"101-108","text":"34(2011), 3, Seite 101-108","volume":"34","issue":"3","year":"2011","extent":"8"},"disp":"Immunotherapy of peritoneal carcinomatosis with the antibody catumaxomab in colon, gastric, or pancreatic cancer an open-label, multicenter, phase I/II trialOnkologie","pubHistory":["1.1978 - 36.2013"],"recId":"300595417","note":["Gesehen am 15.12.2023"]}]} | ||
| SRT | |a STROEHLEINIMMUNOTHER1820 | ||